Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease Pharmaceutical Investing
Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering Pharmaceutical Investing
SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data Pharmaceutical Investing
Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan Pharmaceutical Investing
Ovid Therapeutics Plans to Move into the Phase 3 Trial Based on End-of-Phase 2 Meeting for OV101 Pharmaceutical Investing
VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences Pharmaceutical Investing
